kabutan

Astellas Pharma, Apr-Dec (Cumulative 3Q) Net Income Turns to Loss, Oct-Dec Net Income Turns to Loss

Tue Feb 4, 2025 3:30 pm JST Earnings

4503 Astellas Pharma Inc. 【IFRS】

Earnings Report

Astellas Pharma Inc. <4503> [TSE Prime] announced its financial results (based on IFRS) after the market closed on February 4th (15:30). The consolidated net income/loss for the cumulative third quarter of the fiscal year ending March 2025 (April to December) turned into a loss of 24.1 billion yen (compared to a profit of 50.3 billion yen in the same period last year).

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income/loss for the January to March period (4Q) is expected to turn into a profit of 38.1 billion yen (compared to a loss of 33.2 billion yen in the same period last year).

In the most recent three-month period, from October to December (3Q), the consolidated net income/loss turned to a loss of 97.6 billion yen (compared to a profit of 14.5 billion yen in the same period last year). The operating profit/loss margin drastically worsened from 4.5% in the same period last year to -22.5%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2022 1,164,365 181,279 180,238 144,839 79.4 136.2 Feb 6, 2023 IFRS
Apr - Dec, 2023 1,189,070 74,119 73,630 50,323 28.1 294.9 Feb 5, 2024 IFRS
Apr - Dec, 2024 1,453,029 -22,481 -29,317 -24,149 -13.5 Feb 4, 2025 IFRS
YoY +22.2%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 836,534 -29,638 -31,349 -18,765 -10.5 35 Apr 25, 2024 IFRS
Oct - Mar, 2024 Guidance 964,379 -82,710 -88,042 -59,511 -33.2 37 Jan 24, 2025 IFRS
YoY +15.3% -179.1% -180.8% -217.1% -217.5%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 1,518,619 133,029 132,361 98,714 54.2 60 Apr 27, 2023 IFRS
Mar, 2024 1,603,672 25,518 24,969 17,045 9.5 70 Apr 25, 2024 IFRS
Mar, 2025 Guidance 1,900,000 11,000 1,000 14,000 7.8 74 Jan 24, 2025 IFRS
YoY +18.5% -56.9% -96.0% -17.9% -17.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2023 421,932 18,963 17,312 14,513 8.1 4.5 Feb 5, 2024 IFRS
Jan - Mar, 2024 414,602 -48,601 -48,661 -33,278 -18.6 -11.7 Apr 25, 2024 IFRS
Apr - Jun, 2024 473,124 50,657 50,495 37,603 21.0 10.7 Aug 1, 2024 IFRS
Jul - Sep, 2024 462,497 43,053 38,547 35,908 20.1 9.3 Oct 30, 2024 IFRS
Oct - Dec, 2024 517,408 -116,191 -118,359 -97,660 -54.6 -22.5 Feb 4, 2025 IFRS
YoY +22.6%

Related Articles